Thomas Dayspring: A Decade on Repatha – Stable CAD, No Ischemic Events
Thomas Dayspring, Lipidologist at Early Medical, shared on LinkedIn:
”Anecdotal Study of 1 — Me — I have chronic stable CAD (CAC > 300 15 years ago). With that and other risk factors I had, I easily would have qualified for inclusion in the VESALIUS CV Trial. Fortunately, as soon as PCSK9i came on the market I went on Repatha and now a decade later I am still here – no ischemic events. The day after I got the CAC, I had an invasive coronary angiogram which demonstrated wide open lumens: disease was all in arterial wall. Here is data from GLACOV that shows evolocumab not only kept me alive without any CV issues but likely is causing regression. My apoB on Repatha monotherapy is 50 mg/dL and LDL-C 45 mg/dL. THANK YOU REPATHA, Amgen National Lipid Association European Atherosclerosis Society, American Society for Preventive Cardiology (ASPC).”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch